Compare REX AI Equity Premium Income ETF (AIPI) vs Johnson & Johnson (JNJ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
REX AI Equity Premium Income ETF vs Johnson & Johnson — how do they compare? REX AI Equity Premium Income ETF trades at $36.23, while Johnson & Johnson trades at $265.01 (market cap $643.30B). The key difference: Johnson & Johnson pays a 2.01% dividend while REX AI Equity Premium Income ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, REX AI Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| AIPI | JNJ | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $44.93 | $267.24 |
52-Week Low | $32.45 | $155.17 |
Market Cap | — | $643.30B |
Volume | — | 6,156,228 |
Enterprise Value | — | $676.24B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIPI trades at $37.10, up 1.87% with neutral technical signals. The ETF maintains a high weekly dividend distribution strategy, recently transitioning to weekly payouts. Technical analysis shows mixed signals with bullish moving averages but neutral oscillators, trading near key support at $37. Recent news highlights concerns about NAV erosion risk despite the attractive yield structure.
The outlook remains cautious due to structural limitations in the option-writing strategy that caps upside potential. While the ~34.8% yield appears attractive, sustainability depends heavily on AI market momentum. Investors face NAV erosion risk if technology sector performance falters, requiring careful monitoring of the fund's premium income strategy effectiveness.
Johnson & Johnson (JNJ) trades at $267.24, up 1.6% today, near its 52-week high. The stock shows strong profitability with a 21.83% net income margin and 26.42% ROE, though valuation ratios like P/E of 30.05 are elevated. Recent earnings have mostly beaten expectations, with Q1 2026 EPS of $2.70 surpassing estimates. Technical indicators are bullish, with the price above key moving averages and support at $256.
JNJ's outlook is supported by steady revenue growth and a robust dividend, but high valuation and debt-to-asset ratio of 24.06% pose risks. Analyst consensus is bullish with a $260 price target, though near-term performance may hinge on Q2 2026 earnings due July 15. Investors should weigh solid fundamentals against premium pricing and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About REX AI Equity Premium Income ETF
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
